Core Viewpoint - The company, a leader in China's third-party SPD solutions market, is preparing for an IPO on the Hong Kong Stock Exchange, aiming to leverage its market position and growth potential in the healthcare sector [1][4]. Company Overview - The company submitted its IPO application to the Hong Kong Stock Exchange on January 21, 2025, with Haitong International as the sole sponsor [1]. - It is the largest third-party SPD solution provider in China, holding a market share of 29.2% as of 2024 [1][10]. - The company's SPD solutions include software systems, smart hardware, and professional services, aimed at improving procurement, storage, distribution, and usage management of medical supplies [1]. Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 3.78 billion and a net profit of RMB 0.58 billion [5]. - In the first nine months of 2025, the company achieved revenues of RMB 3.06 billion, reflecting a year-on-year growth of 21.59%, and a net profit of RMB 0.43 billion, up by 7.66% [1][5]. - The gross profit margin for the first nine months of 2025 was approximately 38.79%, while the net profit margin was around 14.14% [5]. Market Dynamics - The overall market size for SPD solutions in China is projected to grow from RMB 184 billion in 2019 to RMB 1,815 billion by 2024, with a compound annual growth rate (CAGR) of 58.1% [8]. - The market is expected to reach RMB 10,574 billion by 2029, with a CAGR of 42.3% from 2024 to 2029 [8]. Deployment and Reach - As of September 30, 2025, the company's SPD solutions were deployed in 116 hospitals across 13 provinces in China, including 3 out of 8 A++ hospitals and 61 out of 91 tertiary hospitals [3]. - The company has achieved significant market penetration in economically developed regions, such as the Yangtze River Delta, with 82 hospitals utilizing its SPD solutions in that area [3]. Competitive Landscape - The company is compared with peers such as Jianhui Information and Saili Medical, which have also undergone IPOs, highlighting its competitive positioning in the market [11].

Company Overview - Guoyi Technology has submitted an application for listing on the Hong Kong Stock Exchange, with Haitong International Capital as its sole sponsor. The company is a leader in the third-party SPD solution market in China, holding a market share of 29.2% as of 2024 [1][3]. - The company primarily generates revenue through SPD solutions and in-hospital IDS solutions, with SPD solutions accounting for 98.2% and 98.5% of revenue in 2024 and the first three quarters of 2025, respectively [3][4]. Financial Performance - The company reported significant revenue growth, with revenues of 378 million yuan and 306 million yuan for 2024 and the first nine months of 2025, representing year-on-year growth of 52.4% and 21.9% [2]. - Net profit showed volatility, with figures of 50 million yuan and 32 million yuan for the same periods, reflecting a year-on-year increase of 994% and a decrease of 16.7%, respectively [2]. - As of November 2025, the company had cash and cash equivalents of 184 million yuan [2]. Market Dynamics - The healthcare market in China is expanding, with total healthcare expenditure projected to reach 9.76 trillion yuan in 2024, driven by an aging population [1]. - The SPD solution market is expected to grow significantly, with a projected compound annual growth rate (CAGR) of 58.1% from 2024 to 2029, reaching a market size of 1,057.4 billion yuan by 2029 [8]. Competitive Landscape - Guoyi Technology is the first third-party SPD solution provider in China and has established a strong market presence, with a significant lead over its competitors [8]. - The third-party SPD solution market is highly concentrated, with the top five players holding approximately 51.7% of the market share [8]. Customer Base and Growth Potential - The company serves a diverse range of hospitals, with 116 hospitals as clients by the first three quarters of 2025, including 91 tertiary hospitals, which account for 78.4% of its client base [5]. - The penetration rate of SPD solutions in tertiary hospitals was approximately 36.1% in 2024, expected to reach 90% by 2029, indicating substantial growth opportunities [10]. Profitability and Cost Management - The company has maintained a positive trend in gross margin, with figures of 37.1%, 41.8%, and 38.8% from 2023 to the first three quarters of 2025 [6]. - The management expense ratio improved by 2.59 percentage points to 10.34% in the first three quarters of 2025, indicating effective cost management [6]. Investment Sentiment - Early investors have seen significant returns, with valuations increasing substantially across multiple funding rounds, although the latest round saw a modest increase [10]. - The company has attracted diverse capital from various investors, indicating strong market interest and confidence in its growth potential [10].

Core Viewpoint - The company, Guoyi Technology, is preparing for an IPO on the Hong Kong Stock Exchange, focusing on its SPD (Supply Chain Process Design) solutions, which are crucial for optimizing hospital supply chains in a rapidly aging population and expanding healthcare market in China [1][10]. Company Overview - Guoyi Technology was established in 2016 and has developed SPD solutions in collaboration with major hospitals, expanding its market presence to various provinces [2][10]. - The company holds a 29.2% market share in China's third-party SPD solutions, making it the largest provider in this sector [1][7]. Financial Performance - Revenue for the first nine months of 2024 and 2025 was reported at 3.78 billion RMB and 3.06 billion RMB, reflecting year-on-year growth of 52.4% and 21.9% respectively [2]. - The net profit for the same periods was 0.5 billion RMB and 0.32 billion RMB, with significant fluctuations, showing a 994% increase in 2024 followed by a 16.7% decrease in 2025 [2]. - The company reported a cash and cash equivalents balance of 1.84 billion RMB as of November 2025 [2]. Revenue Sources - The primary revenue source is the SPD solutions, which accounted for 98.2% and 98.5% of total revenue in 2024 and 2025 respectively [2][3]. - The IDS (In-Hospital Intelligent Delivery System) solutions were introduced in 2024 but have not yet achieved significant commercial success [2][5]. Market Potential - The SPD solutions market in China is projected to grow from 181.5 billion RMB in 2024 to 1,057.4 billion RMB by 2029, with a compound annual growth rate (CAGR) of 42.3% [7]. - The penetration rate of SPD solutions in tertiary hospitals is expected to rise from 36.1% in 2024 to 90% by 2029, indicating substantial growth opportunities [9]. Client Base - As of the first three quarters of 2025, Guoyi Technology served 116 hospitals, with 91 being tertiary hospitals, representing 78.4% of its client base [4][9]. - The company has a low client concentration, with the top five clients contributing only 25% of total revenue [4]. Profitability and Costs - The gross margin has shown an upward trend, with figures of 37.1%, 41.8%, and 38.8% from 2023 to the first three quarters of 2025 [5][6]. - The company has optimized its expense ratios, with a notable decrease in management expense ratio by 2.59 percentage points to 10.34% in 2025 [5][6]. Investment Landscape - Guoyi Technology has attracted significant investment, with its valuation increasing substantially across multiple funding rounds, indicating strong investor confidence [10]. - The company’s latest post-investment valuation reached 1.914 billion RMB, reflecting a 33.8 times increase since the angel round [10].

Group 1 - Company Guoyi Technology has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International as the sole sponsor [1] - According to a Frost & Sullivan report, Guoyi Technology is the largest third-party SPD solution provider in China, holding a market share of 29.2% based on projected 2024 revenue [1] - The SPD (Supply, Processing, and Distribution) solution aims to optimize hospitals' procurement, handling, circulation, and distribution management of medical supplies, addressing issues in traditional supply chain models [1] Group 2 - Guoyi Technology's SPD solution consists of three core components: SPD software system, intelligent hardware, and professional services, which help hospitals reduce operational costs and improve supply management efficiency [1] - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including 3 out of 8 A++ hospitals and 61 out of 91 tertiary hospitals [1] - The company launched an in-hospital IDS (Intelligent Distribution System) solution in 2024, centered around AMR (Autonomous Mobile Robots), utilizing IoT and AI technologies for logistics in critical hospital areas [2] Group 3 - The total transaction value of the SPD solution market in China grew from 18.4 billion yuan in 2019 to 181.5 billion yuan in 2024, with projections to reach 1,057.4 billion yuan by 2029 [2] - The third-party SPD solution market, in terms of revenue, increased from 0.1 billion yuan in 2019 to 1.1 billion yuan in 2024, and is expected to grow to 9.6 billion yuan by 2029 [2] - As of January 15, 2026, Guoyi Technology's product portfolio includes seven AMR models tailored to specific clinical and operational needs within hospital environments [2]

Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted its listing application, with Haitong International as its sole sponsor. The company is a third-party SPD solution provider and is the largest in China by market share, which is 29.2% as of 2024 revenue projections [1]. Group 1: Company Overview - Guoyi Technology was established in 2016 and has deployed its SPD solutions in 116 hospitals across 13 provinces in China by September 30, 2025 [1]. - The company reported revenues of approximately RMB 248 million, RMB 378 million, and RMB 306 million for the fiscal years 2023, 2024, and the first three quarters of 2025, respectively. The corresponding profits were RMB 12.31 million, RMB 57.58 million, and RMB 43.20 million [1]. Group 2: Cash Flow and Financial Performance - The company has experienced negative cash flow from operating activities, with net cash flows of RMB -24.82 million, RMB -53.31 million, and RMB -46.95 million for the respective periods [2]. - Guoyi Technology's cash flow from operating activities is primarily affected by its investment-driven business model, requiring significant upfront expenditures before achieving full revenue generation [2]. - The company anticipates continued negative cash flow from operating activities as it expands its SPD solution portfolio and invests in regional smart cloud warehouses and R&D activities [3]. Group 3: Accounts Receivable and Credit Risk - Trade receivables and notes receivable have been increasing, with amounts of approximately RMB 114 million, RMB 188 million, and RMB 219 million at the end of the respective reporting periods [3][4]. - The turnover days for trade receivables and notes receivable have increased significantly, recorded at 137 days, 145 days, and 180 days for the respective periods [3]. - The company has implemented measures to manage credit risk and improve collection efficiency, including regular assessments of receivables and taking legal action when necessary [4].

Group 1 - The core viewpoint of the article is that Guoyi Technology has submitted an application for listing on the Hong Kong Stock Exchange, with Haitong International as the sole sponsor [1] - According to a Frost & Sullivan report, Guoyi Technology is the largest third-party SPD solution provider in China, with a market share of 29.2% based on projected 2024 revenue [1] - The SPD (Supply, Processing, and Distribution) solution aims to optimize hospitals' procurement, handling, circulation, and distribution management of medical supplies, addressing issues in traditional supply chain models [1] Group 2 - Guoyi Technology's SPD solution consists of three core components: SPD software system, intelligent hardware, and professional services, which help hospitals reduce operational costs and improve supply management efficiency [1] - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including 3 out of 8 A++ hospitals and 61 out of 91 tertiary hospitals [1] - The company launched an in-hospital IDS (Intelligent Distribution System) solution in 2024, centered around AMR (Autonomous Mobile Robots), utilizing IoT and AI technologies for logistics in critical hospital areas [2] Group 3 - The total transaction value of the SPD solution market in China grew from 18.4 billion yuan in 2019 to 181.5 billion yuan in 2024, and is expected to reach 1,057.4 billion yuan by 2029 [2] - The third-party SPD solution market, in terms of revenue, increased from 0.1 billion yuan in 2019 to 1.1 billion yuan in 2024, with projections of reaching 9.6 billion yuan by 2029 [2] - Guoyi Technology's product portfolio includes seven models of AMRs, developed for specific clinical and operational needs within hospital environments as of January 15, 2026 [2]

Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International Capital Limited as its sole sponsor. Guoyi Technology is a leader in China's third-party SPD (Supply, Processing, and Distribution) solutions market, holding a market share of 29.2% based on projected 2024 revenue, and is the first third-party SPD solution provider in China [1][3]. Company Overview - SPD refers to an innovative supply chain model aimed at optimizing hospitals' management of medical supplies. It includes procurement management, inventory handling, and distribution management within hospitals. Traditional supply chain models rely heavily on manual operations and limited information sharing [3]. - Guoyi Technology's SPD solutions consist of three core components: SPD software systems, intelligent hardware, and professional services. These solutions help hospitals reduce operational costs and improve supply management efficiency [3]. - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including three of the eight A++ hospitals that have adopted SPD solutions [3]. Financial Information - Revenue for the years ending December 31 and September 30 is as follows: - 2023: approximately RMB 248.2 million - 2024: approximately RMB 377.9 million - 2025 (as of September 30): approximately RMB 306 million [7][8]. - The total profit and comprehensive income for the same periods are: - 2023: approximately RMB 12.3 million - 2024: approximately RMB 57.6 million - 2025 (as of September 30): approximately RMB 43.2 million [9]. - Gross profit margins for the respective years are: - 2023: 37.1% - 2024: 41.8% - 2025 (as of September 30): 38.8% [10]. Industry Overview - The SPD solutions market in China is projected to grow significantly, with the total market size increasing from RMB 18.4 billion in 2019 to RMB 181.5 billion by 2024, reflecting a compound annual growth rate (CAGR) of 58.1%. By 2029, the market is expected to reach RMB 1,057.4 billion, with a CAGR of 42.3% from 2024 to 2029 [11][12]. - The total transaction value of medical consumables through SPD solutions is expected to grow from RMB 15.9 billion in 2019 to RMB 151.3 billion by 2024, with a CAGR of 56.9%. By 2029, it is projected to reach RMB 724.9 billion [11][12]. - The third-party SPD solutions market is expected to grow from RMB 1 billion in 2019 to RMB 11 billion by 2024, with a CAGR of 75.7%. By 2029, it is projected to reach RMB 9.6 billion, with a CAGR of 53.3% from 2024 to 2029 [14][15].

Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted a listing application to the Hong Kong Stock Exchange, aiming to capitalize on its position as a leader in China's third-party SPD (Supply, Processing, and Distribution) solutions market, with a market share of 29.2% as of 2024 [1][3]. Company Overview - SPD refers to an innovative supply chain model that optimizes the supply and management of medical materials in hospitals, addressing inefficiencies in traditional supply chain methods that rely heavily on manual operations and limited information sharing [3]. - Guoyi Technology's SPD solutions include three core components: SPD software systems, intelligent hardware, and professional services, which help hospitals reduce operational costs and improve supply management efficiency [3]. - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including three of the eight A++ hospitals that have adopted SPD solutions [3]. Product Development - In addition to SPD solutions, Guoyi Technology has developed an in-hospital IDS (Intelligent Distribution System) solution based on IoT and AI technologies, set to launch in 2024 [4]. - The IDS solution will cover logistics for various materials in complex hospital environments, including medical consumables, pharmaceuticals, and medical waste, across critical operational areas such as operating rooms and pharmacies [4]. Financial Information - For the fiscal year ending December 31, 2023, Guoyi Technology reported revenues of approximately RMB 248.2 million, with projected revenues of RMB 377.9 million for 2024 [6]. - The gross profit for the same periods was RMB 92.0 million in 2023 and is expected to rise to RMB 158.2 million in 2024, indicating a gross margin increase from 37.1% to 41.8% [6][8]. - The net profit for the nine months ending September 30, 2024, is projected to be RMB 57.6 million, up from RMB 12.3 million in 2023 [7]. Industry Overview - The overall market for SPD solutions in China is projected to grow from RMB 18.4 billion in 2019 to RMB 181.5 billion by 2024, with a compound annual growth rate (CAGR) of 58.1% [9][10]. - The market for medical consumables through SPD solutions is expected to increase from RMB 15.9 billion in 2019 to RMB 151.3 billion by 2024, with a CAGR of 56.9% [9][10]. - The third-party SPD solutions market is anticipated to grow from RMB 1 billion in 2019 to RMB 11 billion by 2024, with a CAGR of 75.7% [12][13].

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本的全部或任何部分內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 Anhui Zhongji Guoyi Medical Technology Co., Ltd. 安徽中技國醫醫療科技股份有限公司 （「本公司」） （於中華人民共和國成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問及包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據本公司向香港公司註冊 處處長登記的文件作出投資決定，文件將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網 ...

Core Viewpoint - The recent surge in the stock price of Haiwang Bio is attributed to positive market sentiment following the collaboration between three pharmaceutical companies, enhancing confidence in China's innovative drug capabilities [1][8]. Company Evolution - Haiwang Bio has transformed from a regional distributor to a comprehensive biopharmaceutical platform, reflecting the industry's shift from "generic following" to "innovation leading" [3]. - Established in 1992, Haiwang Bio's growth mirrors the consolidation of China's pharmaceutical distribution sector, achieving over 10 billion yuan in revenue by 2015 [3][4]. Business Operations - The company focuses on pharmaceutical and medical device distribution, boasting a logistics network covering over 20 provinces, with significant market share in Shandong and Henan [4]. - Haiwang Bio operates 22 provincial logistics centers and 110 warehouses, with a total storage area exceeding 390,000 square meters, serving nearly 170,000 clients [4][5]. Research and Development - The company has established several innovation platforms and employs a research team of 228, focusing on major diseases and new drug development [5]. - Haiwang Bio has been recognized as a high-tech enterprise and ranks among the top in China's pharmaceutical distribution sector [5][6]. Financial Performance - Despite industry challenges, Haiwang Bio reported a revenue of 30.317 billion yuan in 2024, with a significant reduction in net losses compared to the previous year [7][8]. - The company anticipates a positive long-term growth trajectory as it completes goodwill impairment and optimizes its operations [7]. Industry Opportunities - The Chinese pharmaceutical industry is undergoing a quality upgrade, with policies favoring larger players, positioning Haiwang Bio to expand its market share [8]. - The company is transitioning to provide customized supply chain solutions, enhancing service offerings and operational efficiency [8][9]. Future Growth Potential - Haiwang Bio's NEP018 drug, targeting gastrointestinal tumors, has received clinical trial approval, potentially opening new revenue streams [9]. - The company is well-positioned to leverage its extensive logistics network and innovative service models to capitalize on industry consolidation and growth opportunities [8][9].